Suppr超能文献

双氧疗法治疗低氧性呼吸衰竭:一项回顾性队列研究。

Dual Oxygenation in the Treatment of Hypoxemic Respiratory Failure: A Retrospective Cohort Study.

机构信息

Department of Internal Medicine C, Rambam Health Care Campus, Haifa, Israel.

Department of Internal Medicine C, Rambam Health Care Campus, Haifa, Israel, Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.

出版信息

Isr Med Assoc J. 2023 Sep;25(9):595-600.

Abstract

BACKGROUND

At the beginning of the coronavirus disease 2019 (COVID-19) pandemic, many patients presented with acute hypoxemic respiratory failure, requiring ventilatory support. One treatment method was the addition of a reservoir mask to a high flow nasal cannula (HFNC) (dual oxygenation).

OBJECTIVES

To evaluate the clinical outcomes of combining reservoir mask on top of a high-flow nasal cannula.

METHODS

A retrospective cohort of adult patients who were admitted due to COVID-19 during the first year of the pandemic to Rambam Health Care Campus. The primary endpoint was 30-day mortality. Secondary endpoints were incidence of invasive positive pressure ventilation initiation and admission to the intensive care unit (ICU). Patients who received positive pressure ventilation for reasons other than hypoxemic respiratory failure or who were transferred to another facility while still on HFNC were excluded.

RESULTS

The final analysis included 333 patients; 166 were treated with dual oxygenation and 167 with HFNC only (controls). No significant differences in baseline characteristics were noted between the groups. The dual oxygenation group was slightly older (69.2 ± 14.8 years vs. 65.6 ± 15.5 years, P = 0.034). The 30-day mortality (24.1% vs. 36.5%, P = 0.013), rates of invasive positive pressure ventilation (47% vs. 59.3%, P = 0.024), and ICU admissions (41.6% vs. 52.7%, P = 0.042) were all significantly lower in the dual oxygenation group.

CONCLUSIONS

The addition of reservoir masks to HFNC may improve the oxygenation and overall prognosis in patients with severe hypoxemia due to COVID-19.

摘要

背景

在 2019 年冠状病毒病(COVID-19)大流行开始时,许多患者出现急性低氧性呼吸衰竭,需要通气支持。一种治疗方法是在高流量鼻导管(HFNC)上加储氧面罩(双重氧合)。

目的

评估在高流量鼻导管上增加储氧面罩的临床效果。

方法

回顾性分析了大流行第一年因 COVID-19 住院的成年患者队列。主要终点为 30 天死亡率。次要终点为有创性正压通气启动和入住重症监护病房(ICU)的发生率。排除因低氧性呼吸衰竭以外的原因接受正压通气或在 HFNC 治疗期间转至其他医疗机构的患者。

结果

最终分析纳入 333 例患者;其中 166 例接受双重氧合治疗,167 例仅接受 HFNC 治疗(对照组)。两组患者的基线特征无显著差异。双重氧合组年龄稍大(69.2±14.8 岁 vs. 65.6±15.5 岁,P=0.034)。双重氧合组 30 天死亡率(24.1% vs. 36.5%,P=0.013)、有创性正压通气率(47% vs. 59.3%,P=0.024)和 ICU 入住率(41.6% vs. 52.7%,P=0.042)均显著低于对照组。

结论

HFNC 加储氧面罩可改善 COVID-19 严重低氧血症患者的氧合和整体预后。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验